vs

Side-by-side financial comparison of FIRST US BANCSHARES, INC. (FUSB) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $10.4M, roughly 2.0× FIRST US BANCSHARES, INC.). FIRST US BANCSHARES, INC. runs the higher net margin — 20.4% vs -66.3%, a 86.8% gap on every dollar of revenue. On growth, FIRST US BANCSHARES, INC. posted the faster year-over-year revenue change (7.1% vs -8.7%). Over the past eight quarters, FIRST US BANCSHARES, INC.'s revenue compounded faster (2.6% CAGR vs -0.5%).

First Citizens Bancshares, Inc. is a bank holding company based in Raleigh, North Carolina and one of the largest banks in the United States. Its primary subsidiary is First Citizens Bank, which operates over 500 branches in 23 states. A second subsidiary is Silicon Valley Bank, which operates 39 offices in 15 states.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

FUSB vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
2.0× larger
LUNG
$20.6M
$10.4M
FUSB
Growing faster (revenue YoY)
FUSB
FUSB
+15.7% gap
FUSB
7.1%
-8.7%
LUNG
Higher net margin
FUSB
FUSB
86.8% more per $
FUSB
20.4%
-66.3%
LUNG
Faster 2-yr revenue CAGR
FUSB
FUSB
Annualised
FUSB
2.6%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FUSB
FUSB
LUNG
LUNG
Revenue
$10.4M
$20.6M
Net Profit
$2.1M
$-13.7M
Gross Margin
77.9%
Operating Margin
28.1%
-40.9%
Net Margin
20.4%
-66.3%
Revenue YoY
7.1%
-8.7%
Net Profit YoY
24.2%
5.5%
EPS (diluted)
$0.36
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FUSB
FUSB
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$10.4M
$22.6M
Q3 25
$10.5M
$21.5M
Q2 25
$10.3M
$23.9M
Q1 25
$9.8M
$22.5M
Q4 24
$9.7M
$23.8M
Q3 24
$10.1M
$20.4M
Q2 24
$10.0M
$20.8M
Net Profit
FUSB
FUSB
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$2.1M
$-10.4M
Q3 25
$1.9M
$-14.0M
Q2 25
$155.0K
$-15.2M
Q1 25
$1.8M
$-14.4M
Q4 24
$1.7M
$-13.2M
Q3 24
$2.2M
$-14.1M
Q2 24
$2.1M
$-15.3M
Gross Margin
FUSB
FUSB
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
FUSB
FUSB
LUNG
LUNG
Q1 26
-40.9%
Q4 25
28.1%
-43.8%
Q3 25
23.9%
-66.9%
Q2 25
1.6%
-62.0%
Q1 25
23.8%
-64.6%
Q4 24
23.8%
-56.5%
Q3 24
29.2%
-69.3%
Q2 24
27.4%
-75.2%
Net Margin
FUSB
FUSB
LUNG
LUNG
Q1 26
-66.3%
Q4 25
20.4%
-46.1%
Q3 25
18.4%
-64.9%
Q2 25
1.5%
-63.6%
Q1 25
18.1%
-64.1%
Q4 24
17.6%
-55.4%
Q3 24
22.0%
-69.4%
Q2 24
21.2%
-73.7%
EPS (diluted)
FUSB
FUSB
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$0.36
$-0.25
Q3 25
$0.32
$-0.34
Q2 25
$0.03
$-0.38
Q1 25
$0.29
$-0.36
Q4 24
$0.29
$-0.33
Q3 24
$0.36
$-0.36
Q2 24
$0.34
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FUSB
FUSB
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$73.5M
$61.6M
Total DebtLower is stronger
$10.9M
$37.3M
Stockholders' EquityBook value
$105.6M
$45.8M
Total Assets
$1.2B
$120.0M
Debt / EquityLower = less leverage
0.10×
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FUSB
FUSB
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$73.5M
$69.8M
Q3 25
$54.7M
$76.5M
Q2 25
$54.0M
$75.5M
Q1 25
$56.0M
$74.6M
Q4 24
$47.2M
$70.9M
Q3 24
$82.3M
$63.3M
Q2 24
$58.2M
$63.5M
Total Debt
FUSB
FUSB
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$10.9M
$37.1M
Q3 25
$10.9M
$37.1M
Q2 25
$10.9M
$37.1M
Q1 25
$10.9M
$37.2M
Q4 24
$10.9M
$37.2M
Q3 24
$10.9M
$37.2M
Q2 24
$10.8M
$37.2M
Stockholders' Equity
FUSB
FUSB
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$105.6M
$54.1M
Q3 25
$104.2M
$60.0M
Q2 25
$101.9M
$69.1M
Q1 25
$101.2M
$77.7M
Q4 24
$98.6M
$85.8M
Q3 24
$98.5M
$93.9M
Q2 24
$93.8M
$101.2M
Total Assets
FUSB
FUSB
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$1.2B
$129.3M
Q3 25
$1.1B
$138.3M
Q2 25
$1.1B
$147.2M
Q1 25
$1.1B
$150.7M
Q4 24
$1.1B
$162.8M
Q3 24
$1.1B
$167.4M
Q2 24
$1.1B
$172.6M
Debt / Equity
FUSB
FUSB
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.10×
0.69×
Q3 25
0.10×
0.62×
Q2 25
0.11×
0.54×
Q1 25
0.11×
0.48×
Q4 24
0.11×
0.43×
Q3 24
0.11×
0.40×
Q2 24
0.12×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FUSB
FUSB
LUNG
LUNG
Operating Cash FlowLast quarter
$12.3M
Free Cash FlowOCF − Capex
$9.1M
FCF MarginFCF / Revenue
87.2%
Capex IntensityCapex / Revenue
31.1%
Cash ConversionOCF / Net Profit
5.79×
TTM Free Cash FlowTrailing 4 quarters
$16.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FUSB
FUSB
LUNG
LUNG
Q1 26
Q4 25
$12.3M
$-7.1M
Q3 25
$4.2M
$-8.2M
Q2 25
$3.9M
$-3.9M
Q1 25
$1.8M
$-13.2M
Q4 24
$7.8M
$-6.7M
Q3 24
$1.9M
$-7.2M
Q2 24
$2.5M
$-5.8M
Free Cash Flow
FUSB
FUSB
LUNG
LUNG
Q1 26
Q4 25
$9.1M
$-7.1M
Q3 25
$3.6M
$-8.3M
Q2 25
$1.6M
$-4.0M
Q1 25
$1.7M
$-13.5M
Q4 24
$5.7M
$-6.8M
Q3 24
$1.3M
$-7.7M
Q2 24
$2.3M
$-6.2M
FCF Margin
FUSB
FUSB
LUNG
LUNG
Q1 26
Q4 25
87.2%
-31.4%
Q3 25
34.2%
-38.4%
Q2 25
16.0%
-16.6%
Q1 25
17.2%
-60.0%
Q4 24
58.2%
-28.8%
Q3 24
12.7%
-37.6%
Q2 24
23.5%
-30.0%
Capex Intensity
FUSB
FUSB
LUNG
LUNG
Q1 26
Q4 25
31.1%
0.1%
Q3 25
5.9%
0.4%
Q2 25
21.8%
0.2%
Q1 25
0.7%
1.3%
Q4 24
21.6%
0.5%
Q3 24
6.6%
2.0%
Q2 24
2.0%
2.3%
Cash Conversion
FUSB
FUSB
LUNG
LUNG
Q1 26
Q4 25
5.79×
Q3 25
2.18×
Q2 25
25.16×
Q1 25
0.99×
Q4 24
4.53×
Q3 24
0.87×
Q2 24
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons